NEO News Alert Neogenomics Inc (NEO) 4.03 12/25/2014 05:38:4

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Neogenomics Inc (NEO) 4.03 $NEO

NeoGenomics, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and the Northwestern Medicine Developmental Therapeutics Institute Launch Collaborative Translational Research Program
PR Newswire - Tue Dec 16, 6:00AM CST
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a research agreement with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) that will provide the basis to initiate a broad-spectrum translational program designed to expand the established clinical utility of comprehensive genomic profiling technologies in the development of oncology therapeutics from early pre-clinical studies to clinical practice.
NEO: 4.03 (-0.10)

United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 14.90 (+0.05), HH: 0.53 (unch), BRLI: 31.82 (+0.55), NEO: 4.03 (-0.10), DGX: 67.94 (-0.16), LH: 107.69 (+0.56), GHDX: 32.44 (+1.32)

United States Medical and Diagnostic Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6lcqc/medical_and) has announced the addition of Plunkett Research Ltd's new report "Medical and Diagnostic Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical and Diagnostic Laboratories Industry (U.S.) to reach $80.8 billion by 2021. - Medical and Diagnostic Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alliance Healthcare Services Inc - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - NeoGenomics Inc - Quest Diagnostics Inc - RadNet Inc For more information visit http://www.researchandmarkets.com/research/k6...edical_and Source: Plunkett Research Ltd
HH: 0.53 (unch), BRLI: 31.82 (+0.55), RDNT: 9.41 (-0.08), NEO: 4.03 (-0.10), DGX: 67.94 (-0.16), LH: 107.69 (+0.56), GHDX: 32.44 (+1.32)

N-of-One Selected by NeoGenomics to Provide Clinical Evidence for Interpreting Solid Tumor Next-Generation Sequencing Tests
Business Wire - Tue Dec 02, 7:31AM CST
N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced an agreement with NeoGenomics, Inc., a leading provider of cancer-focused genetic and molecular testing services. Under this agreement, N-of-One will provide clinical and interpretive evidence for NeoGenomics solid tumor next-generation sequencing (NGS) tests being used by community pathologists and oncologists. Financial terms of the agreement are not disclosed.
NEO: 4.03 (-0.10)

Midday Gainers/ Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 11:49AM CST

FRM: 7.61 (unch), NEO: 4.03 (-0.10), AU: 8.39 (+0.24), FNHC: 25.30 (+0.45), AMS: 2.50 (-0.02), NYMX: 0.38 (unch), AMDA: 0.64 (-0.01), CVD: 103.73 (+0.02), GBIM: 7.29 (unch), RCAP: 11.23 (+0.26), KBIO: 1.63 (-0.04), COOL: 1.15 (+0.14), SAPE: 24.81 (-0.01), XTLB: 2.21 (+0.03), GERN: 3.06 (+0.05), ANIP: 55.24 (+1.79), BBLU: 1.15 (-0.03), NXTD: 2.46 (-0.09), AP: 19.03 (+0.47), ALQA: 3.96 (-0.02)

NeoGenomics' (NEO) CEO Doug VanOort on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:31AM CDT

NEO: 4.03 (-0.10)

Neogenomics raises full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:51AM CDT

NEO: 4.03 (-0.10)

Neogenomics beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:26AM CDT

NEO: 4.03 (-0.10)

NeoGenomics Reports 38% increase in Revenue to a Record $23.2 Million and Adjusted EBITDA of $2.6 Million for the Third Quarter of 2014
PR Newswire - Thu Oct 30, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the third quarter of 2014.
NEO: 4.03 (-0.10)

NeoGenomics to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, October 30, 2014
ACCESSWIRE - Wed Oct 29, 3:13PM CDT
FT. MYERS, FL / ACCESSWIRE / October 29, 2014 / NeoGenomics Inc. (NASDAQ:NEO) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Thursday, October 30, 2014 at 11:00 AM Eastern Time.
NEO: 4.03 (-0.10)

NeoGenomics is First to Offer Molecular Testing for Resistance to Bruton Tyrosin Kinase Inhibitors for Chronic Lymphocytic Leukemia
PR Newswire - Thu Oct 23, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has launched new tests for the detection of mutations in the Bruton tyrosine kinase (BTK) and PLC-gama2 genes for predicting acquired resistance to BTK inhibitors. In addition, NeoGenomics launched a lymphoma profiling test specifically to predict susceptibility to BTK inhibitors and test for mutations in CXCR4, CD79B, MYD88, and CARD11 genes in various types of lymphoma.
NEO: 4.03 (-0.10)

NeoGenomics Launches 315 Gene Next Generation Sequencing Test for Solid Tumor Discovery Profiling
PR Newswire - Thu Oct 16, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the addition of a new comprehensive solid tumor profiling test designed for clinical discovery and to support clinical trials. The test utilizes next generation sequencing ("NGS" to analyze variants in the coding sequence of 315 genes and uses conventional Fluorescent in Situ Hybridization ("FISH" methods to identify large deletions, amplifications and translocations in 9 different chromosomal loci.
NEO: 4.03 (-0.10)

NeoGenomics Appoints Robert J. Shovlin as Chief Operating Officer
PR Newswire - Mon Sep 29, 4:00PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today the appointment of Robert Shovlin as Chief Operating Officer. This appointment will be effective as of Mr. Shovlin's expected start date of October 13, 2014.
NEO: 4.03 (-0.10)

NeoGenomics Schedules its Q3 2014 Earnings Release for October 30, 2014
PR Newswire - Wed Sep 24, 2:28PM CDT
NeoGenomics, Inc. (NASDAQ: NEO)announced today that it plans to release its third quarter 2014 financial results on Thursday October 30, 2014.
NEO: 4.03 (-0.10)

3 Under-$10 Stocks Triggering Breakout Trades
at The Street - Wed Sep 10, 6:00AM CDT
Keep these stocks under $10 on your trading radar.
NEO: 4.03 (-0.10), DPRX: 11.25 (-0.07), GCAP: 8.80 (-0.04)

5 Under-$10 Stocks Making Big Moves Higher
at The Street - Fri Sep 05, 7:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
IRMD: 12.64 (+0.14), MY: 2.04 (-0.02), NEO: 4.03 (-0.10), LINC: 2.80 (-0.06), ARO: 2.30 (-0.03)

5 Breakout Stocks Under $10 Set to Soar
at The Street - Thu Aug 28, 1:39PM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
CAMT: 3.05 (+0.03), AGRX: 6.90 (+0.06), NEO: 4.03 (-0.10), CYTR: 2.58 (+0.03), ATRS: 2.65 (+0.03), TA: 12.21 (+0.01)

NeoGenomics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option
PR Newswire - Fri Aug 22, 6:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company" , a leading provider of cancer-focused genetic testing services, today announced that it has closed on the public offering of an additional 1.05 million shares of common stock at an offering price of $4.60 per share as a result of the exercise in full of the underwriters' over-allotment option. The total gross proceeds of the offering, including the exercise in full of the over-allotment option were approximately $37.0 million from the sale of a total of 8.05 million common shares. The net proceeds to the Company, after deducting the underwriters' discount and other estimated expenses will be approximately $34.6 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes including potential acquisitions and the repayment of debt.
NEO: 4.03 (-0.10)

NeoGenomics Announces Pricing of $32.2 Million Public Offering
PR Newswire - Fri Aug 15, 8:00AM CDT
NeoGenomics, Inc. (NASDAQ: NEO) (the "Company" , a leading provider of cancer-focused genetic testing services, today announced that it has priced an underwritten public offering of 7.0 million shares of common stock at a price to the public of $4.60 per share. The transaction is expected to close on August 20, 2014 and will result in gross proceeds to NeoGenomics of $32.2 million. The net proceeds to the Company, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $30.0 million. The Company plans to use the net proceeds for working capital, capital expenditures and for general corporate purposes, including potential acquisitions and the repayment of debt. NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover over-allotments, if any.
NEO: 4.03 (-0.10)

NeoGenomics Announces Public Offering of Common Stock
PR Newswire - Thu Aug 14, 3:01PM CDT
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares in the offering are to be sold by NeoGenomics.
NEO: 4.03 (-0.10)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 113

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 107

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 100

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading

Top 5 Most Recently Viewed Articles

ICG Enterprise Trust plc Announces Share Repurchase Details

Updated Category News Views 159

ICG Enterprise Trust plc Share Buyback Announcement ICG Enterprise Trust plc (the “Company”) The Company has announced a recent development regarding its share buyback initiative. On a significant date, it repurchased 15,000 of its own shares aimed to be held as treasury shares, with each share valued at an average price of 1450 pence. Details of the Transaction...

Continue Reading
Converge Technology Solutions Shares Third Quarter 2024 Insights

Updated Category News Views 217

Converge Technology Solutions Announces Preliminary Q3 Results Converge Technology Solutions Corp. (CTS) has released its preliminary unaudited financial results for the third quarter of 2024. The company is committed to delivering insightful updates to its stakeholders as part of its transparency approach. The company stated that all figures are presented in Canadian...

Continue Reading
Discovery Silver Corp. Unveils 2023 ESG Report

Updated Category News Views 104

Discovery Silver Corp. Releases 2023 ESG Report Key Highlights: Earned Quality Environmental Certification from the Mexican Government Recognized as a Socially Responsible Enterprise by the Mexican Center for Philanthropy Achieved Great Place to Work Certification Discovery Silver Corp. (TSX: DSV, OTCQX: DSVSF) is excited to announce the publication of its 2023...

Continue Reading
Final Call for Subscription in IDEX Biometrics Offering Today

Updated Category News Views 152

Important Subscription Period Details for IDEX Biometrics Today marks a significant turning point for IDEX Biometrics ASA as the subscription period for their subsequent offering of shares closes. The company previously announced that they aim to issue up to 600 million new shares at a remarkable subscription price of NOK 0.01 per share. This offering, essential for...

Continue Reading
Dundee Corporation Strengthens Position in Greenheart Gold Inc.

Updated Category News Views 33

Overview of Recent Acquisition Dundee Corporation (TSX: DC.A) has announced that its wholly-owned subsidiary, Dundee Resources Limited, recently acquired 2,000,000 common shares of Greenheart Gold Inc. (TSXV: GHRT) at a price of C$0.50 per share, totaling an investment of C$1,000,000. This acquisition is part of the Issuer's bought deal private placement and signifies...

Continue Reading